| Dr Kaveh N Najafi, DO | |
|
1044 S Fair Oaks Ave, Suite 101, Pasadena, CA 91105-2622 | |
| (626) 768-4415 | |
| (626) 403-0321 |
| Full Name | Dr Kaveh N Najafi |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 18 Years |
| Location | 1044 S Fair Oaks Ave, Pasadena, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083906242 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Scottsdale Osborn Medical Center | Scottsdale, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Honorhealth Ambulatory | 5991603110 | 406 |
News Archive
The standard of care for kidney cancer patients continues to improve. The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer.
There are two main challenges and both relate to manufacturing. The first one is to make sure you can manufacture therapies with reasonable costs and the second one is to make sure that you can balance the capacity you need with the demands.
Leading global interdisciplinary design firm Perkins+Will today released a new report examining the detrimental impact of building materials and products on asthma.
Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.
› Verified 3 days ago
| Entity Name | Honorhealth Ambulatory |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407050917 PECOS PAC ID: 5991603110 Enrollment ID: O20071005000449 |
News Archive
The standard of care for kidney cancer patients continues to improve. The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer.
There are two main challenges and both relate to manufacturing. The first one is to make sure you can manufacture therapies with reasonable costs and the second one is to make sure that you can balance the capacity you need with the demands.
Leading global interdisciplinary design firm Perkins+Will today released a new report examining the detrimental impact of building materials and products on asthma.
Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kaveh N Najafi, DO 35 E Glenarm St, Pasadena, CA 91105-3418 Ph: (626) 768-4415 | Dr Kaveh N Najafi, DO 1044 S Fair Oaks Ave, Suite 101, Pasadena, CA 91105-2622 Ph: (626) 768-4415 |
News Archive
The standard of care for kidney cancer patients continues to improve. The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer.
There are two main challenges and both relate to manufacturing. The first one is to make sure you can manufacture therapies with reasonable costs and the second one is to make sure that you can balance the capacity you need with the demands.
Leading global interdisciplinary design firm Perkins+Will today released a new report examining the detrimental impact of building materials and products on asthma.
Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.
› Verified 3 days ago
Dr. David J Lourie, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 10 Congress St Ste 512, Pasadena, CA 91105 Phone: 626-793-7955 Fax: 626-793-7577 | |
Dr. George F Williams, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 39 Congress St, #300, Pasadena, CA 91105 Phone: 626-577-8620 Fax: 626-577-8622 | |
Jean Claude Henry, MD Surgery Medicare: May Accept Medicare Assignments Practice Location: 655 S Euclid Ave, Pasadena, CA 91106 Phone: 626-272-7411 | |
Dr. Richard John Vasak, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 W California Blvd, Gme, Pasadena, CA 91105 Phone: 626-397-5187 | |
Dr. James S Andersen, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 625 S Fair Oaks Ave Ste 270&380, Pasadena, CA 91105 Phone: 424-314-0177 Fax: 424-314-0180 | |
Michael Ashley Albin, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 31 West Bellevue Drive, Pasadena, CA 91105 Phone: 626-584-6116 Fax: 626-584-7886 |